ReviewCureus2025
Management of Antidepressant-Induced Sexual Dysfunction: A Literature Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Novel anxiolytic-antidepressant combinations TF-1 and TF-2 and their intervention mechanisms in a mouse model of comorbid anxiety and depression (CAD).Frontiers in pharmacology · 2026Article
- Sexual dysfunction associated with antidepressants and antipsychotics: a structured narrative review of mechanisms, assessment, and personalized management.Frontiers in psychiatry · 2026Review
- Plant-derived bioactives in depression-related and antidepressant-associated sexual dysfunction: a narrative review.Frontiers in nutrition · 2026Review
- Perceived Erectile Dysfunction in a Single Young Male With Multiple Associated Psychological Factors.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although selective serotonin reuptake inhibitors (SSRIs) are the mainstay of treatment for various psychiatric conditions, including but not limited to major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, and bulimia nervosa, sexual side effects from these medications are common. These side effects include decreased libido, difficulty with arousal and erection, and delayed or absent orgasm, which can be troubling for many patients and impact adherence to treatment and quality of life. This is an important distinction from decreased libido that can be seen in the natural course of depression; the sexual dysfunction discussed in this paper is due to an adverse effect of SSRIs. The goal of this narrative review is to explore the effectiveness of switching antidepressant therapy or adding adjunctive medications or herbal supplements in alleviating antidepressant-induced sexual dysfunction (AISD). An electronic literature search was performed on PubMed to identify full-text, English-language articles that discussed antidepressant-induced sexual dysfunction (AISD). Selected articles were published between 1996 and 2023. Replacing one antidepressant class for another with a more favorable side effect profile (e.g., mirtazapine, nefazodone, and vortioxetine) may be effective for some patients, especially if the initial antidepressive treatment was not sufficient in controlling the symptoms caused by the primary mental illness. Several adjunctive medications and supplements also show promise in the management of AISD, including bupropion and saffron (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.